BiotechTube

Bevacizumab + Irinotecan Sucrosofate

Phase 2Completed
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Platinum-Resistant Fallopian Tube Carcinoma

Conditions

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma

Trial Timeline

Mar 16, 2021 → Oct 25, 2021

NCT ID
NCT04753216

About Bevacizumab + Irinotecan Sucrosofate

Bevacizumab + Irinotecan Sucrosofate is a phase 2 stage product being developed by Ipsen for Platinum-Resistant Fallopian Tube Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04753216. Target conditions include Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04753216Phase 2Completed

Competing Products

16 competing products in Platinum-Resistant Fallopian Tube Carcinoma

See all competitors
ProductCompanyStageHype Score
PRGN-3005 UltraCAR-T cells + PRGN-3005 UltraCAR-T cellsPrecigenPhase 1
28
Niraparib + AnlotinibSun PharmaceuticalPhase 2
52
E7050 + CetuximabEisaiPhase 1/2
41
PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd + PLD 40mg/m2 ivgtt q4wJiangsu Hengrui MedicinePhase 2
52
Batiraxcept + DurvalumabAstraZenecaPhase 1/2
41
olaparib+cediranib combination therapy + durvalumab + olaparib combination therapy + durvalumab + chemotherapy treatment + durvalumab + tremelimumab + chemotherapy treatment + durvalumab + tremelimumab + paclitaxel treatment + durvalumab +chemotherapy treatmentAstraZenecaPhase 2
52
Nemvaleukin and Pembrolizumab Combination + Pembrolizumab + Nemvaleukin + Pegylated Liposomal Doxorubicin (PLD) + Paclitaxel + Topotecan + GemcitabineMerckPhase 3
77
CRS-207 + Epacadostat + PembrolizumabIncytePhase 1/2
38
Rina-S + Paclitaxel + Topotecan + Pegylated liposomal doxorubicin (PLD) + GemcitabineGenmabPhase 3
74
Gemcitabine + N-803 + M-CENKImmunityBioPhase 2
49
Drug Product De-TIL-0255Nurix TherapeuticsPhase 1
28
Pegylated Liposomal Doxorubicin + SL-172154 + Mirvetuximab + SL-172154Shattuck LabsPhase 1
25
CTIM-76Context TherapeuticsPhase 1
25
LorigerlimabMacroGenicsPhase 2
44
olvimulogene nanivacirepvec + Platinum chemotherapy: carboplatin (preferred) or cisplatin + Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin + Bevacizumab (or biosimilar)GeneluxPhase 3
69
PHI-101 administrationiBioPhase 1
25

Other Products from Ipsen

AbobotulinumtoxinA + PlaceboApproved
82
lanreotide acetateApproved
82
Tigan® + PlaceboApproved
82
Diosmectite (Smecta®)Approved
82
lanreotide (Autogel formulation)Approved
82